3B Blackbio DX Ltd
Incorporated in 2011, 3B BlackBio Dx Ltd manufactures and exports PCR based Molecular Diagnostic kits, PCR Enzymes & PCR Reagents, and agrochemical-based products[1]
- Market Cap ₹ 1,097 Cr.
- Current Price ₹ 1,278
- High / Low ₹ 2,350 / 1,175
- Stock P/E 21.9
- Book Value ₹ 346
- Dividend Yield 0.31 %
- ROCE 25.5 %
- ROE 19.0 %
- Face Value ₹ 10.0
Pros
- Company has reduced debt.
- Company is almost debt free.
- Company has delivered good profit growth of 139% CAGR over last 5 years
- Debtor days have improved from 179 to 142 days.
Cons
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Healthcare Services Healthcare Service Provider
Part of BSE Healthcare BSE SmallCap BSE Allcap
Quarterly Results
Standalone Figures in Rs. Crores / View Consolidated
Profit & Loss
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 21 | 18 | 16 | 13 | 16 | 12 | 14 | 14 | 16 | 59 | 71 | 91 | 95 | |
| 20 | 17 | 15 | 12 | 14 | 12 | 14 | 16 | 17 | 30 | 36 | 41 | 43 | |
| Operating Profit | 1 | 1 | 1 | 1 | 1 | 0 | -0 | -1 | -1 | 30 | 35 | 50 | 52 |
| OPM % | 6% | 7% | 7% | 8% | 7% | 4% | -2% | -8% | -8% | 50% | 50% | 55% | 55% |
| 0 | 0 | 0 | 0 | 0 | 1 | 1 | 4 | 10 | 7 | 12 | 15 | 16 | |
| Interest | 1 | 1 | 1 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Depreciation | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 1 |
| Profit before tax | 0 | 0 | 0 | 0 | 1 | 0 | 1 | 2 | 8 | 36 | 46 | 64 | 67 |
| Tax % | 14% | 21% | 23% | 14% | 9% | 2% | 0% | 18% | 5% | 26% | 26% | 26% | |
| 0 | 0 | 0 | 0 | 1 | 0 | 1 | 2 | 8 | 26 | 34 | 48 | 50 | |
| EPS in Rs | 0.59 | 0.34 | 0.30 | 0.36 | 0.81 | 0.67 | 0.81 | 2.29 | 10.67 | 35.19 | 39.86 | 55.41 | 58.37 |
| Dividend Payout % | 0% | 0% | 0% | 83% | 61% | 74% | 86% | 392% | 98% | 8% | 8% | 7% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 18% |
| 5 Years: | 46% |
| 3 Years: | 80% |
| TTM: | 14% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 71% |
| 5 Years: | 139% |
| 3 Years: | 81% |
| TTM: | 16% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 64% |
| 5 Years: | 32% |
| 3 Years: | 45% |
| 1 Year: | -34% |
| Return on Equity | |
|---|---|
| 10 Years: | 17% |
| 5 Years: | 19% |
| 3 Years: | 19% |
| Last Year: | 19% |
Balance Sheet
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 6 | 6 | 6 | 6 | 6 | 6 | 7 | 7 | 7 | 9 | 9 | 9 | 9 |
| Reserves | 4 | 4 | 5 | 5 | 9 | 9 | 13 | 15 | 16 | 188 | 219 | 264 | 289 |
| 6 | 7 | 7 | 8 | 6 | 6 | 4 | 2 | 3 | 2 | 1 | 0 | 0 | |
| 7 | 7 | 6 | 5 | 5 | 5 | 4 | 4 | 5 | 16 | 21 | 24 | 16 | |
| Total Liabilities | 24 | 25 | 24 | 24 | 26 | 27 | 28 | 29 | 32 | 214 | 250 | 297 | 314 |
| 3 | 3 | 3 | 3 | 2 | 2 | 2 | 2 | 3 | 7 | 7 | 6 | 7 | |
| CWIP | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Investments | 0 | 0 | 0 | 1 | 1 | 1 | 4 | 4 | 4 | 102 | 128 | 167 | 186 |
| 21 | 22 | 21 | 21 | 22 | 23 | 22 | 23 | 25 | 105 | 116 | 124 | 121 | |
| Total Assets | 24 | 25 | 24 | 24 | 26 | 27 | 28 | 29 | 32 | 214 | 250 | 297 | 314 |
Cash Flows
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 0 | 0 | 1 | 0 | -1 | 0 | 1 | 3 | 8 | 21 | 28 | 44 | |
| -0 | -0 | -0 | 0 | -0 | -0 | -2 | -0 | -2 | -8 | -20 | -34 | |
| 0 | -0 | -1 | -0 | 1 | -0 | 1 | -2 | -6 | -3 | -4 | -3 | |
| Net Cash Flow | 0 | 0 | 0 | 0 | 0 | -0 | 0 | 1 | 0 | 10 | 5 | 8 |
Ratios
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 217 | 271 | 303 | 371 | 332 | 426 | 382 | 358 | 337 | 206 | 188 | 142 |
| Inventory Days | 106 | 128 | 121 | 190 | 108 | 176 | 116 | 88 | 81 | 154 | 144 | 122 |
| Days Payable | 175 | 204 | 190 | 237 | 115 | 156 | 108 | 95 | 108 | 63 | 65 | 24 |
| Cash Conversion Cycle | 148 | 196 | 234 | 323 | 326 | 447 | 390 | 351 | 311 | 297 | 267 | 240 |
| Working Capital Days | 150 | 183 | 218 | 279 | 328 | 427 | 438 | 422 | 391 | 248 | 225 | 174 |
| ROCE % | 7% | 6% | 5% | 6% | 6% | 4% | 4% | 9% | 34% | 32% | 22% | 26% |
Documents
Announcements
-
Announcement under Regulation 30 (LODR)-Newspaper Publication
1 Dec - Window for Re-lodgement of Transfer Requests of Physical shares
-
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
29 Nov - Nov 29, 2025 one-to-one with Seven Canyons Advisors; reiterated Q2-FY26 presentation; no unpublished price-sensitive information.
- Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation 24 Nov
-
Vigilance Awareness Week 2025
20 Nov - Urges stakeholders to take CVC e-pledge for Vigilance Awareness Week 2025 (notice dated Nov 20, 2025).
-
Announcement under Regulation 30 (LODR)-Newspaper Publication
19 Nov - Window for Re-lodgement of Transfer Requests of Physical Shares.
Annual reports
-
Financial Year 2025
from bse
-
Financial Year 2024
from bse
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
-
Financial Year 2011
from bse
Concalls
-
Nov 2025TranscriptAI SummaryPPT
-
Aug 2025Transcript PPT REC
-
May 2025TranscriptAI SummaryPPT
-
Feb 2025TranscriptAI SummaryPPT
-
Nov 2024TranscriptAI SummaryPPT
-
Aug 2024TranscriptAI SummaryPPT
-
May 2024TranscriptAI SummaryPPT
-
Feb 2024TranscriptAI SummaryPPT
-
Nov 2023TranscriptAI SummaryPPT
-
Aug 2023TranscriptAI SummaryPPT
-
May 2023TranscriptAI SummaryPPT
-
Feb 2023TranscriptAI SummaryPPT
-
Nov 2022TranscriptAI SummaryPPT
-
Sep 2022TranscriptAI SummaryPPT
-
Aug 2022TranscriptAI SummaryPPT
-
May 2022TranscriptAI SummaryPPT
-
Feb 2022TranscriptAI SummaryPPT
-
Nov 2021TranscriptAI SummaryPPT
-
Sep 2021TranscriptAI SummaryPPT
-
Jul 2021TranscriptAI SummaryPPT
-
Jun 2021TranscriptAI SummaryPPT
-
Feb 2021TranscriptAI SummaryPPT
-
Feb 2021TranscriptAI SummaryPPT
-
Nov 2020TranscriptAI SummaryPPT
-
Sep 2020TranscriptAI SummaryPPT
-
Jul 2020TranscriptAI SummaryPPT
-
Jun 2020TranscriptAI SummaryPPT
-
Feb 2020TranscriptAI SummaryPPT
-
Nov 2019TranscriptAI SummaryPPT
-
Jul 2019TranscriptAI SummaryPPT
-
May 2019TranscriptAI SummaryPPT
-
Jan 2019TranscriptAI SummaryPPT
-
Nov 2018TranscriptAI SummaryPPT
-
Aug 2018TranscriptAI SummaryPPT
-
May 2018TranscriptAI SummaryPPT
-
Feb 2018TranscriptAI SummaryPPT
-
Nov 2017TranscriptAI SummaryPPT
-
Jul 2017TranscriptAI SummaryPPT
-
Feb 2017TranscriptAI SummaryPPT
Business Segments[1][2]
A) Diagnostics Business (81% of FY23 revenue)
3BDL is part of an Indo-Spanish JV and was formed by amalgamation with its parent company Kilpest India Limited. Company is an ISO 13485:2016 certified, GMP-compliant biotech R&D organization and is engaged in the design, development, manufacturing, and commercialization of Rapid tests, PCR-based Molecular Diagnostic kits, PCR Enzymes & PCR Reagents, NGS-based Molecular Diagnostic Kit